plumbagin has been researched along with Liver Failure, Acute in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, X; Da, Y; Gao, F; Guan, Z; Kong, L; Li, D; Li, Y; Miao, G; Qiao, L; Wang, D; Wang, H; Xue, Z; Yang, F; Yang, L; Yao, Z; Zhang, H; Zhang, L; Zhang, Q; Zhang, R; Zhang, Y | 1 |
1 other study(ies) available for plumbagin and Liver Failure, Acute
| Article | Year |
|---|---|
Plumbagin protects liver against fulminant hepatic failure and chronic liver fibrosis via inhibiting inflammation and collagen production.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Apoptosis; Chemical and Drug Induced Liver Injury; Collagen Type I; Collagen Type III; Cytoprotection; Female; Hepatic Stellate Cells; Humans; Liver; Liver Cirrhosis, Experimental; Liver Failure, Acute; Liver Regeneration; Mice; Mice, Inbred ICR; Myofibroblasts; Naphthoquinones; NF-kappa B; p300-CBP Transcription Factors; Phosphorylation; Proto-Oncogene Proteins c-akt; RAW 264.7 Cells; Signal Transduction; STAT3 Transcription Factor; Thioacetamide; TOR Serine-Threonine Kinases | 2016 |